A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire.

Area of Science:

• Pharmacology
• Urology
• Clinical Trials

Background:

• Premature ejaculation (PE) is a common male sexual dysfunction.
• Selective serotonin reuptuptake inhibitors (SSRIs) are frequently used off-label for PE treatment.
• Limited comparative data exists for commonly prescribed SSRIs in PE management.

Purpose of the Study:

• To compare the efficacy of three SSRIs—paroxetine, fluoxetine, and escitalopram—in treating premature ejaculation (PE).
• To evaluate treatment outcomes using a validated questionnaire for assessing ejaculation time.

Main Methods:

• A prospective, single-blinded, randomized clinical trial involving 100 men with PE.
• Participants were assigned to receive daily doses of fluoxetine (20 mg), escitalopram (10 mg), or paroxetine (20 mg) for four weeks.
• Efficacy was assessed using the Adult Inventory of Pharmacological Effects (AIPE) questionnaire.

Main Results:

• All 100 participants showed a significant increase in AIPE total scores post-treatment.
• No statistically significant differences were observed in any AIPE item scores among the three SSRI groups.
• All investigated SSRIs were well-tolerated by the study participants.

Conclusions:

• Paroxetine, fluoxetine, and escitalopram show comparable efficacy in improving ejaculation latency for men with PE.
• Further long-term, large-scale studies are warranted to confirm sustained treatment effects.
• SSRIs represent a viable therapeutic option for managing premature ejaculation.